Wegovy Vs Ozempic

If you have been researching weight loss injections in the UK, you have almost certainly come across both Wegovy and Ozempic, and you would not be alone in wondering whether they are actually the same thing. Both medications contain semaglutide, both are injected once a week, and both come from the same manufacturer, Novo Nordisk. Yet they are prescribed for different purposes, at different doses, and they carry different price tags. Understanding the distinction matters, because choosing the wrong one could mean you are either under-dosed for meaningful weight loss or using a diabetes medication without clinical supervision for that specific use.

Quick Summary

Both Wegovy and Ozempic contain the same active ingredient, semaglutide, but they are licensed for entirely different conditions and used at different dose ceilings. Wegovy is the MHRA-approved option for chronic weight management, while Ozempic is licensed exclusively for type 2 diabetes in the UK.

• Wegovy reaches a maximum dose of 2.4 mg weekly; Ozempic peaks at 2 mg weekly for diabetes
• Wegovy is approved for adults with a BMI of 30 or above, or 27 with a weight-related health condition
• Ozempic is prescribed for type 2 diabetes and is not MHRA-approved for weight loss
• Clinical trials show Wegovy produces an average 15% body weight reduction over 68 weeks
• Both medications carry similar side effect profiles but differ in prescribing criteria and cost

Table of Contents

1. What Are Wegovy and Ozempic?
2. Wegovy vs Ozempic: Key Differences Explained
3. Dose Escalation and Maximum Dose Comparison
4. Who Should Use Wegovy and Who Should Use Ozempic?
5. Side Effects You Need to Know About
6. Cost, NHS Access, and Private Prescriptions in 2026
7. Full Comparison Table
8. Key Takeaways
9. When to Seek Professional Advice
10. Scientific References
11. FAQs

What Are Wegovy and Ozempic?

To understand the debate around Wegovy vs Ozempic, it helps to start with what both medications actually are at their core. Both are GLP-1 receptor agonists — a class of drug that mimics the glucagon-like peptide-1 hormone that the gut naturally releases after eating. This hormone signals the brain to reduce appetite, slows gastric emptying so you feel fuller for longer, and helps regulate blood sugar levels. The active ingredient in both products is semaglutide, which is a synthetic, long-acting analogue of natural GLP-1.

Ozempic was the first semaglutide product to reach the UK market. It was developed specifically for adults with type 2 diabetes and is used alongside diet and exercise to improve glycaemic control. Its approval was based on the SUSTAIN clinical trial programme, which demonstrated significant reductions in HbA1c (blood sugar) and also — as a secondary benefit — reductions in body weight. That secondary weight loss effect is partly what led to its widespread off-label use for weight management, although this is not what it is licensed for in the UK.

Wegovy came later, specifically developed and dosed to maximise weight loss as its primary clinical outcome. It was approved by the MHRA for use in the UK and is backed by the STEP clinical trial programme, which enrolled tens of thousands of participants and produced some of the most impressive weight loss data ever seen for a pharmaceutical intervention. Explore our weight loss treatment options to see how Wegovy fits into a complete clinical approach to managing excess weight.

• Both medications contain semaglutide and are made by Novo Nordisk
• Ozempic was developed for type 2 diabetes; Wegovy was developed for obesity
• GLP-1 receptor agonists reduce appetite, slow digestion, and stabilise blood sugar
• Wegovy's STEP trials specifically measured weight loss as the primary endpoint

Wegovy vs Ozempic: Key Differences That Actually Matter to Patients

When people compare Wegovy vs Ozempic, the most important differences go beyond the label. The first is the approved indication. In the UK, Ozempic is only licensed to treat type 2 diabetes. Wegovy, however, holds a specific MHRA licence for chronic weight management in adults with a BMI of 30 kg/m² or above, or a BMI of 27 kg/m² or above if the patient has at least one weight-related comorbidity such as hypertension, dyslipidaemia, or obstructive sleep apnoea. This distinction matters enormously for prescribers and patients alike.

The second critical difference is the dose. Wegovy's maintenance dose is 2.4 mg of semaglutide per week, while Ozempic's highest approved dose for diabetes is 2 mg per week. That might sound like a small numerical gap, but in clinical terms it translates into significantly greater appetite suppression and meaningfully better weight loss outcomes. The STEP 1 trial demonstrated that participants on Wegovy 2.4 mg lost an average of 14.9% of their body weight over 68 weeks, compared to the 4–6% typically seen with lower doses of semaglutide used in diabetes management.

The third difference is the pen device itself. Wegovy and Ozempic come in distinct pre-filled injection pens that are not interchangeable. Wegovy pens are designed to deliver the specific doses used in the weight loss escalation schedule (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg), whereas Ozempic pens deliver doses of 0.25 mg, 0.5 mg, 1 mg, and 2 mg for diabetes. Attempting to use one pen to replicate the dose schedule of the other is not safe or clinically appropriate.

• Wegovy is MHRA-licensed for weight management; Ozempic is licensed for type 2 diabetes only
• Wegovy has a higher maintenance dose of 2.4 mg vs Ozempic's 2 mg ceiling
• The pen devices are distinct and not interchangeable between the two products
• Using Ozempic off-label for weight loss means you are not receiving the optimum therapeutic dose

Dose Escalation Schedules: How Wegovy and Ozempic Differ Step by Step

One of the most practical concerns people raise when comparing these two medications is how the dosing actually works over time. Both products use a gradual dose escalation strategy to allow the body to adjust to semaglutide and reduce the severity of gastrointestinal side effects such as nausea. However, the schedules diverge, particularly in their upper stages.

For Ozempic, the standard escalation for diabetes starts at 0.25 mg weekly for four weeks, then 0.5 mg weekly. Depending on glycaemic response, a prescriber may increase this to 1 mg and subsequently to 2 mg. The 2 mg dose is the newest and highest approved dose for diabetes and was introduced to the UK market following the SUSTAIN FORTE trial. Importantly, Ozempic does not escalate to 2.4 mg because that dose is not part of its licensed diabetes indication.

Wegovy's escalation schedule is longer and specifically designed to reach that 2.4 mg target safely. Patients start at 0.25 mg weekly for the first four weeks, then move to 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg — each stage lasting approximately four weeks. The inclusion of the 1.7 mg step is unique to Wegovy and helps patients tolerate the jump to the full maintenance dose. Browse our clinically supervised weight loss programmes to learn more about how Wegovy dosing is managed in practice.

• Ozempic escalates up to 2 mg over several weeks for diabetes management
• Wegovy uses a five-stage escalation ending at 2.4 mg for weight management
• The 1.7 mg stage in Wegovy is not part of Ozempic's escalation protocol
• Proper escalation reduces nausea, vomiting, and gastrointestinal discomfort
• Never skip dose stages without speaking to a prescriber

Who Should Use Wegovy and Who Should Use Ozempic?

This question sits at the heart of every conversation patients and prescribers have about these two treatments. The straightforward answer is: if your primary goal is weight loss and you do not have type 2 diabetes, Wegovy is the clinically appropriate choice. If you have type 2 diabetes and need improved glycaemic control, Ozempic is the licensed and recommended option — though it may also provide some degree of weight loss as a secondary benefit.

The complexity arises when a patient has both type 2 diabetes and obesity. In those cases, the prescriber needs to consider which condition is the priority and whether switching to Wegovy to benefit from the higher dose and the specific weight management licence makes clinical sense. In 2026, NICE guidance around specialist weight management services has evolved to allow Wegovy access through structured pathways, which has clarified many of these crossover scenarios.

There is also the matter of cardiovascular risk. The SELECT trial, published in 2023, demonstrated that semaglutide 2.4 mg (Wegovy) reduced the risk of major adverse cardiovascular events in adults with obesity and established cardiovascular disease who did not have diabetes. This was a landmark finding that helped cement Wegovy's role as more than a cosmetic weight loss tool. In contrast, Ozempic's cardiovascular benefit data derives primarily from trials in diabetic populations via the SUSTAIN-6 trial.

• Choose Wegovy if you are overweight or obese without type 2 diabetes and need clinically supervised weight loss
• Choose Ozempic if you have type 2 diabetes and need better blood sugar control
• If you have both conditions, discuss with your prescriber which medication better addresses your primary clinical need
• Wegovy has additional cardiovascular risk reduction evidence from the SELECT trial in non-diabetic patients

Side Effects You Need to Know About Before Starting Either Medication

Because both medications share the same active ingredient, their side effect profiles are broadly similar. The most commonly reported issues are gastrointestinal in nature and are most likely to occur during dose escalation stages. These include nausea, vomiting, diarrhoea, constipation, abdominal discomfort, and bloating. For most patients, these effects are mild to moderate and tend to settle as the body adapts to each new dose stage over four weeks.

More serious but less common side effects include pancreatitis, gallbladder problems (including gallstones), and a theoretical risk of thyroid C-cell tumours based on animal studies — though this has not been conclusively demonstrated in humans. Both medications carry a contraindication in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). These contraindications apply equally to Wegovy and Ozempic regardless of the dose.

One concern unique to Wegovy's higher dose is that gastrointestinal side effects may be slightly more pronounced due to the 2.4 mg maintenance dose. This is why the five-stage escalation schedule is so important — rushing through dose stages increases the likelihood of adverse effects that might cause a patient to discontinue treatment unnecessarily. If you experience persistent or severe side effects on either medication, you should contact your prescriber promptly rather than stopping abruptly without guidance.

• Common side effects: nausea, vomiting, diarrhoea, constipation — usually dose-related and temporary
• Serious but rare: pancreatitis, gallstones, hypoglycaemia (especially if combined with insulin or sulfonylureas)
• Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2
• Higher Wegovy doses may produce slightly more pronounced gastrointestinal effects — do not skip escalation stages
• Discontinue gradually under prescriber supervision if side effects become unmanageable

Cost, NHS Access, and Private Prescriptions in 2026

Cost remains one of the most significant barriers for patients looking to access semaglutide-based treatments in the UK. Ozempic is available on NHS prescription for type 2 diabetes patients who meet the relevant clinical criteria. It is not available on the NHS for weight loss purposes. Wegovy is now accessible through specialist NHS weight management services for eligible patients, following NICE Technology Appraisal guidance — but NHS waiting lists can be long, and eligibility criteria are strict.

For patients who want to access Wegovy privately without waiting for NHS referral, the private prescription route is a well-established and legally compliant option. Registered online pharmacies and prescribing services can issue a private prescription after a clinical consultation, and this is the route most commonly taken by patients in 2026. Prices vary between providers, so it is important to use a pharmacy that is regulated by the GPhC and uses GMC-registered or GPhC-registered prescribers.

In terms of cost comparison, Ozempic prescribed privately for weight loss purposes is both clinically inappropriate and potentially more expensive when you consider that you may need to use higher quantities of pens to attempt to replicate the Wegovy dose — which is not recommended. Wegovy, when obtained through a legitimate private prescribing service like Cured Pharmacy, offers a transparent, clinically supervised pathway at a competitive price. View our Wegovy weight loss treatment range with free private prescription included.

• Ozempic is available on NHS for type 2 diabetes; not funded for weight loss
• Wegovy is accessible via NHS specialist weight management services with a referral
• Private Wegovy prescriptions are available through GPhC-regulated online pharmacies
• Using Ozempic off-label for weight loss is not cost-effective or clinically appropriate
• Always verify your online pharmacy's GPhC registration before purchasing any prescription medication

Full Wegovy vs Ozempic Comparison Table

Feature	Wegovy (Semaglutide)	Ozempic (Semaglutide)
Active Ingredient	Semaglutide	Semaglutide
Manufacturer	Novo Nordisk	Novo Nordisk
UK Licensed Indication	Chronic weight management (obesity/overweight with comorbidities)	Type 2 diabetes mellitus
Maximum Weekly Dose	2.4 mg	2 mg
Dose Escalation Stages	0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg	0.25 mg → 0.5 mg → 1 mg → 2 mg
Administration	Once weekly subcutaneous injection	Once weekly subcutaneous injection
Average Weight Loss in Trials	~15% body weight (STEP 1, 68 weeks)	~4–6% body weight (SUSTAIN trials)
NHS Availability	Via specialist weight management services	Yes, for type 2 diabetes
Private Prescription Available	Yes	Yes (for diabetes only)
Cardiovascular Trial Data	SELECT trial (non-diabetic with obesity + CVD)	SUSTAIN-6 trial (type 2 diabetes)
Pen Device Interchangeable?	No — Wegovy-specific pen	No — Ozempic-specific pen
Common Side Effects	Nausea, vomiting, diarrhoea, constipation	Nausea, vomiting, diarrhoea, constipation
BMI Eligibility (Weight Use)	BMI ≥30, or ≥27 with comorbidity	Not approved for weight loss use

Key Takeaways

• Wegovy and Ozempic both contain semaglutide but are licensed for entirely different conditions — do not assume they are interchangeable
• Wegovy delivers a higher maximum dose of 2.4 mg weekly, which is why it produces significantly greater weight loss than Ozempic in clinical trials
• If your goal is weight loss, Wegovy is the clinically and legally correct choice in the UK, not Ozempic used off-label
• Both medications share similar side effects, but these are generally manageable with proper dose escalation under prescriber supervision
• Private prescriptions for Wegovy are available through regulated UK pharmacies in 2026, making access straightforward for eligible patients

When to Seek Professional Advice

You should speak to a qualified prescriber before starting either Wegovy or Ozempic. This applies whether you are seeking treatment for weight management or type 2 diabetes. A prescriber will assess your full medical history, review any medications you are currently taking, and confirm which product is appropriate for your specific clinical needs.

Seek urgent medical attention if you experience any of the following while on semaglutide:

• Severe and persistent abdominal pain that radiates to the back (potential pancreatitis)
• Symptoms of gallbladder problems such as right-sided abdominal pain, fever, or yellowing of the skin
• Significant vision changes or signs of diabetic retinopathy worsening
• Signs of a serious allergic reaction including facial swelling, difficulty breathing, or a widespread rash
• Persistent vomiting or inability to keep fluids down for more than 24 hours

If you are currently taking Ozempic for diabetes and are considering switching to Wegovy to enhance weight loss, never make this change without clinical guidance. Your prescriber will need to review your diabetes management plan to ensure glycaemic control is maintained throughout the transition. You can speak to one of our GPhC-registered prescribing pharmacists at Cured Pharmacy through an online consultation, which takes under three minutes to complete.

Scientific References

1. NICE Technology Appraisal TA875 — Semaglutide for managing overweight and obesity (Wegovy), National Institute for Health and Care Excellence, 2023
2. Wegovy 2.4 mg Summary of Product Characteristics, Electronic Medicines Compendium (eMC), Novo Nordisk Ltd
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial), The BMJ, 2024

Frequently Asked Questions

How long does it take to see weight loss results with Wegovy?

Weight loss results with Wegovy typically begin within the first four weeks, with more noticeable changes appearing by weeks eight to twelve. Clinical trials show that the most significant weight reduction occurs between months three and twelve, with participants losing an average of 15% of their body weight over 68 weeks at the full 2.4 mg maintenance dose.

Is it safe to use Ozempic off-label for weight loss in the UK?

Using Ozempic off-label for weight loss in the UK is not recommended by NICE or the MHRA. While Ozempic contains semaglutide, it is only licensed for type 2 diabetes management at doses up to 1 mg. Wegovy is the MHRA-approved option for weight management and delivers a higher 2.4 mg maintenance dose with proven clinical evidence.

Can you switch from Ozempic to Wegovy without starting the dose escalation again?

Switching from Ozempic to Wegovy does not always require restarting from the lowest dose, but this depends on your current Ozempic dose and how well you have tolerated it. Your prescriber will review your treatment history and map you to the equivalent Wegovy starting point, ensuring a safe and clinically appropriate transition without unnecessary side effects.

What is the maximum dose of Wegovy compared to Ozempic?

The maximum dose of Wegovy is 2.4 mg semaglutide per week, which is specifically approved for chronic weight management. Ozempic reaches a maximum of 2 mg per week for type 2 diabetes. The higher maintenance dose in Wegovy is the primary reason it produces greater average weight loss compared to Ozempic in clinical studies.